{
  "nctId": "NCT04235660",
  "briefTitle": "Y90 Radiation Segmentectomy vs SBRT for HCC",
  "officialTitle": "Yttrium-90 Radiation Segmentectomy Versus Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Early Stage Hepatocellular Carcinoma (HCC): A Pilot Study",
  "protocolDocument": {
    "nctId": "NCT04235660",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-12-15",
    "uploadDate": "2023-04-06T11:37",
    "size": 872017,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04235660/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "SINGLE",
  "enrollmentInfo": {
    "enrollmentCount": 2,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-07-22",
    "completionDate": "2022-03-08",
    "primaryCompletionDate": "2022-03-08",
    "firstSubmitDate": "2020-01-15",
    "firstPostDate": "2020-01-22"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Ability to provide written informed consent and HIPAA authorization\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged ≥ 18 years at time of informed consent\n* Solitary HCC (≤3 cm) diagnosed by imaging (LI-RADS 4-5) or histology\n* Childs-Pugh score ≤ 7\n* ECOG performance status 0-1\n* Tumor location/characteristics eligible for either SBRT or Y90 therapy as deemed by local tumor board\n* Adequate organ function defined as:\n\n  1. serum bilirubin \\< 4.0 mg/dL ,\n  2. albumin \\> 2 g/dL\n\nExclusion Criteria:\n\n* Any prior locoregional therapy to the target tumor\n* Any prior radiation therapy to the liver\n* Pregnancy or lactation: Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:\n\n  i. Has undergone a hysterectomy or bilateral oophorectomy; or ii. Has been naturally amenorrheic for at least 24 consecutive months\n* Known severe allergic reaction (anaphylaxis) to iodinated contrast\n* Coagulopathy (platelets \\< 50 K/mm3 and/or INR \\> 2) not correctable by transfusion\n* Macrovascular invasion or extrahepatic HCC",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Feasibility of Recruitment (Recruitment Rate)",
        "description": "Feasibility of recruitment will be measured by evaluating the proportion of patients enrolled versus those approached for the study after they have been determined to be a candidate.",
        "timeFrame": "24 months"
      }
    ],
    "secondary": [
      {
        "measure": "Proportion of Patients With Any Toxicities",
        "description": "the proportion of patients with any toxicities (≥ grade 4) using CTCAE between RS and SBRT for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC).",
        "timeFrame": "16 months for the first subject and 4 months for the second"
      },
      {
        "measure": "Mean Change in Hepatobiliary Function",
        "description": "the mean change in hepatobiliary function, as measured 3 months after treatment using a functional HIDA scan, between RS and SBRT for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC).",
        "timeFrame": "16 months for the first subject and 4 months for the second"
      },
      {
        "measure": "Mean Change in Functional Assessment of Cancer Therapy- General (FACT-G) Score",
        "description": "the mean change in patient-reported outcomes from baseline, at 1, 3 and 6 months, between RS and SBRT, for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC), using the Functional Assessment of Cancer Therapy- General (FACT-G). scale goes from 0-108 with a higher score being better.",
        "timeFrame": "6 months"
      },
      {
        "measure": "Mean Change in Comprehensive Score for Financial Toxicity",
        "description": "the mean change in patient-reported outcomes from baseline, at 1, 3 and 6 months, between RS and SBRT, for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC), using the Comprehensive Score for Financial Toxicity (COST). scale is from 0-44 with higher being bettter",
        "timeFrame": "6 months"
      },
      {
        "measure": "Disease-free Survival (DFS) Rates of RS and SBRT",
        "description": "the disease-free survival (DFS) rates of RS and SBRT at 2 years using mRECIST on CT or MR for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC).",
        "timeFrame": "16 months for the first subject and 4 months for the second"
      },
      {
        "measure": "Time-to-secondary Treatment (TTST) Between RS and SBRT",
        "description": "time-to-secondary treatment (TTST) between RS and SBRT for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC) up to 2 years after initial treatment.",
        "timeFrame": "16 months for the first subject and 4 months for the second"
      },
      {
        "measure": "Objective Response Rate",
        "description": "the objective response rate (ORR) of radiation segmentectomy (RS) and stereotactic body radiation therapy (SBRT) as measured at 6 months using mRECIST (appendix IV) for patients with small (≤3 cm) solitary hepatocellular carcinoma (HCC) to better allow for an appropriately powered trial evaluating the efficacy of these treatments.",
        "timeFrame": "6 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 7,
      "otherCount": 0,
      "totalCount": 8
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 74,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:54.793Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}